| 摘要 |
The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.
|
| 申请人 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES;RAMOT OF TEL AVIV UNIVERSITY;BRENNEMAN, DOUGLAS, E.;SPONG, CATHERINE, Y.;GOZES, ILLANA;BASSAN, MERAV;ZAMOSTIANO, RACHEL |
发明人 |
BRENNEMAN, DOUGLAS, E.;SPONG, CATHERINE, Y.;GOZES, ILLANA;BASSAN, MERAV;ZAMOSTIANO, RACHEL |
